Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes

Heart failure (HF), especially with preserved ejection fraction (HFpEF) is common in older patients with type 2 diabetes (T2DM), but often not recognized. Early HF detection in older T2DM patients may be worth...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Source Type: research

Related Links:

This study aims to shed light on this debatable issue.MethodsAn electronic database search (Cochrane Library, PubMed and Embase) was performed using two groups of terms [ “sodium glucose cotransporter2 inhibitor”, “dapagliflozin”, “canagliflozin”, “empagliflozin”, “ertugliflozin”] AND [“major adverse cardiac events”, “MACE”, “cardiovascular death or hospitalization for heart failure”, non-fatal myocardial infarction”, “non-fatal st roke”, “cardiovascular death”, “hospitalization for heart fail...
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
Type 2 diabetes is a major risk factor for the development of heart disease.1 At the beginning of the last century, or even before, several authors described a possible association between diabetes and heart failure (HF).2 However, according to the Heart Failure Association of the European Society of Cardiology guideline for the treatment of type 2 diabetes and HF, the first report of this association, excluding other risk factors, was published in 1954.
Source: Radcliffe Cardiology - Category: Cardiology Authors: Source Type: research
  Answer: No—unless you do it for more than a few months. After a few months, the upfront metabolic and weight benefits will begin to reverse and new health problems arise. We know this with confidence. I raise this question once again because more and more people are coming to me reporting problems. It may take months, even years, but the long-term consequences can be quite serious. Achieving ketosis by engaging in a very low-carbohydrate, high-fat lifestyle is—without a doubt—an effective means of losing weight, breaking insulin and leptin resistance, reversing type 2 diabetes and fatty liver, redu...
Source: Wheat Belly Blog - Category: Cardiology Authors: Tags: ketones bowel flora ketogenic ketotic undoctored wheat belly Source Type: blogs
AbstractBackground and AimsDiabetes mellitus (DM) can cause left ventricular (LV) diastolic dysfunction, leading to heart failure with preserved ejection fraction (HFpEF). Dipeptidyl peptidase IV (DPP-IV) inhibitors have failed to reduce hospitalization due to HF in type 2 DM (T2D) patients in a large-scale clinical trial, despite their cardiovascular protective effects. Therefore, it is important to investigate whether DPP-IV inhibitors can improve LV diastolic dysfunction in T2D patients. The aim of the study was to evaluate whether teneligliptin, the strongest of the DPP-IV inhibitors, improves LV dysfunction or prevent...
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
CONCLUSION: The current analysis showed that treatment with DPP-4 inhibitors did not significantly increase cardiovascular outcomes in these patients with T2DM indicating that those drugs might be safe to use in terms of cardiovascular events. PMID: 30832701 [PubMed - in process]
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
AbstractPurpose of ReviewDiabetes mellitus (DM) has become a rising epidemic in the last century, more pressing in the last few decades with the exponential rise of obesity, and has become one of the leading causes of death worldwide.Recent FindingsGenetic variants have also been a new field of epidemiology research to determine the underlying genetic component of those risk factors and the association of DM with CVD.SummaryIn light of its significant prevalence, patients remain unaware of their disease progression that arises from genetic and metabolic risk factors. As compared to non-diabetics, those with type 2 DM carry...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research
Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases worldwide, which leads to myocardial dysfunction and even heart failure in long-term follow-up[1 –3]. The potential pathomechanism of diabetic myocardial damage is multifactorial and result in diffuse myocardial fibrosis [4,5]. Myocardial fibrosis is related to the pathogenesis of left ventricle hypertrophy and has been confirmed in the middle or later stage of diabetic cardialmyopathy, which paly an important role in cardiac structure change and the abnormality of cardiac function[67].
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
Authors: Singh AK, Singh R Abstract INTRODUCTION: Heart failure (HF) in type 2 diabetes mellitus (T2DM) poses a significant increase in mortality. Until recently, anti-diabetic drugs have not been shown to reduce hospitalization due to heart failure (hHF). While thiazolidinedione class and saxagliptin has shown a significantly increased risk, sodium-glucose linked co-transporter 2 inhibitors (SGLT-2Is) have demonstrated a significant reduction in the risk of hHF. Areas covered: We systematically searched the database of PubMed, Embase, ClinicalTrials.gov and International conference presentation up to December 25, ...
Source: Expert Review of Clinical Pharmacology - Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research
We aimed to investigate the association between diabetes duration and the subsequent occurrence of heart failure (HF) in type 2 diabetes mellitus (T2DM) patients without clinical cardiovascular disease. In this single-center, observational cohort study, a total of 3724 T2DM patients were stratified by diabetes duration into three 5-year interval subgroups. The primary outcomes were the occurrence of new-onset HF and all-cause mortality. HF incidence (P 
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Significant and constant increase in hospitalization due to heart failure in Spain over 15 year period. Eur J Intern Med. 2019 Feb 28;: Authors: Méndez-Bailón M, Jiménez-García R, Hernández-Barrera V, Comín-Colet J, Esteban-Hernández J, de Miguel-Díez J, de Miguel-Yanes JM, Muñoz-Rivas N, Lorenzo-Villalba N, López-de-Andrés A Abstract BACKGROUND: To examine trends in the incidence, characteristics, and in-hospital outcomes of heart failure (HF) hospitalizations from 2001 to 2015 in Spain. METHODS: Using the Spanish Nat...
Source: European Journal of Internal Medicine - Category: Internal Medicine Authors: Tags: Eur J Intern Med Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Failure